Hospitalizations in New York City are on the rise as new COVID strains spread rapidly

Hospitalizations in New York City are on the rise because of the spread of novel COVID-19 subvariants that are more adept at circumventing immunity Flu and respiratory syncytial virus, or RSV, cases are also on the rise.

According to state data, approximately 1,100 COVID patients were hospitalized as of Oct. 24, up from 750 in mid-September, as reported by the New York Times. Case numbers have remained stable, albeit with many people testing at home and no data being collected, those figures are not accurate.

According to CDC data, the omicron sublineages known as BQ.1 and BQ.1.1 accounted for 42.5% of all cases in the New York region in the week ending Oct. 29, up from 37% the previous week.

This was higher than the BA.5 omicron subvariant, which accounted for 35.7% of new cases in the New York area in the previous week. The two sublineages were not even registered three weeks ago, illustrating how quickly they are spreading.

Experts are particularly concerned about a widespread outbreak of RSV, which can cause respiratory issues in young children and the elderly and for which no vaccination is presently available.

However, Pfizer Inc. reported on Tuesday that data from a late-stage trial of an RSV vaccine showed that it was beneficial in avoiding severe sickness in children as young as 6 months old.

The vaccine, administered to expectant moms, achieved a vaccination effectiveness of 81.8% in newborns from birth to the first 90 days of life in the Phase 3 trial. 69.4% effectiveness was established in the trial over the first 6 months of life.

Pfizer stated that it plans to file its first U.S. regulatory application for the vaccine by the end of 2022, followed by applications to additional regulatory bodies. It will also submit the trial results to a scientific journal for peer assessment.

Coronavirus Updates: Since the coronavirus epidemic began, MarketWatch’s daily roundup has been compiling and reporting on all the newest events every day.

Other COVID-19 news to be aware of:

According to Reuters, Apple supplier Foxconn announced Tuesday that it has increased bonuses for workers at its Zhengzhou facility in central China in order to quell resentment over COVID limitations and retain staff at the massive iPhone assembly site. According to the official WeChat account of Foxconn’s Zhengzhou factory, daily bonuses for employees of a Foxconn unit responsible for creating electronics including smartphones have been increased to 400 yuan ($55) per day for November from 100 yuan. Workers deserted the site over the weekend to evade COVID limits after complaining on social media about their treatment and provisions.

To get more updates on Healthcare Industry: Dermal fillers market rise up to USD 9.45 billion by 2030